Updated:
Virtual Therapeutics
Virtual Therapeutics engineers FDA-authorized immersive treatments, using EndeavorRx for ADHD and Bloom VR for mental fitness.
Virtual Therapeutics
Virtual Therapeutics engineers evidence-based digital interventions that work at the intersection of cognitive science and interactive media design. The firm’s landmark product, EndeavorRx, received FDA de novo authorization as the first prescription video game treatment, targeting the neural networks that govern attention and impulse control in children with ADHD. The non-prescription form extends that approval to a broader commercial audience. A second product suite, Breakthrough, pairs the Bloom VR mental-fitness program with AI-driven biofeedback to address anxiety, sleep disruption and stress resilience for health systems, schools and corporate employers. The company constructs its pipeline using what it calls an "efficient commercial model" — a departure from the slow, inflexible pharmaceutical economics that it argues have constrained digital therapeutic returns. On the distribution side, Virtual Therapeutics pursues parallel go-to-market motions: a direct-to-consumer channel, embedded deployments inside large healthcare provider networks, and enterprise relationships with employers and educators. Confirmed deployments span at least three therapeutic categories — ADHD, anxiety management, and sleep improvement — built atop the proprietary RIBS platform that handles delivery, assessment and reimbursement logistics. The firm publicly highlights partnerships with unnamed "world's best healthcare, behavioral health, and technology leaders" to align its tools with existing clinical and payment ecosystems. The company operates out of Kirkland, Washington, with a phone presence at (425) 821-8001. No public headcount or capital-inflow figures are disclosed. The website carries a testimonial from former U.S. Senate Majority Leader and surgeon Bill Frist, who opines on VR's potential to "radically improve health and wellbeing." No structured philanthropic vehicle, adjacent fund, or co-investment club is cited. Virtual Therapeutics functions as a digital therapeutic developer seeking to replace portions of the traditional pharma supply chain with a software-and-content factory. Its structural differentiator is the attempt to collapse clinical validation, behavioral-engagement design and reimbursement-enablement into a single platform stack — a posture that distinguishes it from pure VR content studios, contract research organizations and conventional pharmacy-benefit arrangements.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Kirkland
Corporate office
13905 NE 128th Street, Suite 200, Kirkland, WA 98034, United States
Sector focus
Frequently asked questions
What is the regulatory status of Virtual Therapeutics' products?
EndeavorRx is authorized by the FDA as the first prescription digital therapeutic for ADHD, targeting attention and impulse-control networks. A subsequent non-prescription version expands access without a prescription requirement. The Breakthrough suite, including Bloom VR, operates as a general wellness and mental-fitness tool positioned outside traditional medical-device pathways.
How does Virtual Therapeutics distribute its digital treatments?
The firm pursues a three-channel model: direct-to-consumer sales, integration with large healthcare providers for in-clinic and at-home use, and enterprise contracts with employers and schools. Its RIBS platform underpins delivery, clinical assessment and reimbursement processing, designed to embed these tools into insurance and health-system billing workflows.
What is the RIBS platform?
RIBS is Virtual Therapeutics' proprietary software backbone for delivering, assessing and reimbursing its digital treatments. The system replaces elements of the traditional pharmaceutical distribution chain with a flexible, speed-optimized model that the company argues offers higher economic upside and faster iteration than legacy pharma economics.
Which therapeutic areas does Virtual Therapeutics target?
The firm's active indications include pediatric ADHD (EndeavorRx), anxiety management and sleep improvement (Breakthrough / Bloom VR). Its published pipeline vision extends to stress relief, phobias, PTSD, depression, pain management, autism social-cognition training, stroke rehabilitation, smoking cessation and physician empathy training, though no regulatory filings are cited for those areas.
Who leads Virtual Therapeutics, and what backing does it have?
No named principals, investors or funding rounds are disclosed in the firm's public materials. A letter of support from former U.S. Senate Majority Leader Bill Frist appears on the company's website, framing VR as a transformative health tool, but no operational or board role is specified.
How does Virtual Therapeutics compare to other digital therapeutic companies?
Virtual Therapeutics competes in the prescription-digital-therapeutic category alongside firms such as Akili Interactive (the original FDA clearance holder for EndeavorRx) and Pear Therapeutics (bankruptcy 2023). Virtual Therapeutics' differentiation lies in combining a multi-indication platform approach with an explicit critique of pharma's commercial model, seeking to control the full stack from content design through reimbursement.
Does Virtual Therapeutics have any exclusive partnerships or co-development deals?
The firm states it has partnered with unnamed world-class healthcare, behavioral-health and technology organizations to co-develop solutions. No specific partner names, deal terms or exclusive licensing arrangements are publicly identified, making the scope of these alliances difficult to assess.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: